Neurovascular Nuggets: Your Weekly Dose of Neurovascular Innovation

Neurovascular-Nugget 19_ Unraveling Stroke Clot Composition for Better Treatment

Thu, 26 Mar 2026 15:21:38 GMT

🧠🧠The clinical implications of this study are:

Thrombus composition could be an important factor underlying the variable efficacy of r-tPA in stroke patients. Knowing the composition of the occluding thrombus may help predict response to r-tPA and guide treatment decisions.
Imaging modalities like CT and MRI, which can identify RBC-rich thrombi, may be useful to predict r-tPA susceptibility. RBC-poor thrombi, not detectable by these methods, are likely to be r-tPA resistant.
For patients with r-tPA resistant thrombi (RBC-poor/platelet-rich), combining r-tPA with drugs targeting thrombus components like DNA (DNase-1) or VWF (diNAC) could be a promising approach to improve thrombolysis and recanalization rates.
A composition-tailored thrombolytic strategy, using r-tPA alone for RBC-rich thrombi and r-tPA + DNase-1/diNAC for RBC-poor thrombi, may expand the range of thrombi amenable to successful pharmacological lysis, especially benefiting patients currently failing r-tPA therapy.
If proven safe in terms of bleeding risk, a combination therapy targeting both fibrin and non-fibrin components could potentially be given to all patients, eliminating the need to determine thrombus composition beforehand.

Neurovascular Nugget_ Re-evaluating Thrombectomy in MEVO - Insights from DISTAL and ESCAPE-MeVO

Thu, 26 Mar 2026 15:21:37 GMT

"Given the methodological heterogeneity and distinct patient populations enrolled in the DISTAL and ESCAPE-MeVO trials, caution is warranted when attempting to synthesize or directly compare their findings. The disparate designs and inclusion criteria limit the cumulative interpretability of the results, necessitating independent evaluation of each study's conclusions. Furthermore, the following nuances necessitate careful consideration when interpreting each study's findings, as they may significantly influence the reader's understanding of the efficacy and safety of endovascular treatment for medium and distal vessel occlusions."🔴 Vessel Definition & Patient Population:DISTAL (Broader): Diluted EVT benefit due to inclusion of potentially less severe distal occlusions and exclusion of known EVT-responsive dominant M2s. Impact: Underestimation of EVT potential.ESCAPE-MeVO (Narrower): Targeted a more specific group, but chosen locations may have been less amenable to EVT or higher risk. Impact: Potential for negative result.Overall Impact: Differences may explain DISTAL's neutral result vs. ESCAPE-MeVO's harm signal.🔴 Time Window:DISTAL (Longer - 24h): Allowed more patients but increased irreversible damage and spontaneous recanalization. Impact: Diluted treatment effect.ESCAPE-MeVO (Shorter - 12h): Enriched for potentially responsive patients but may have missed others who could benefit. Impact: Potentially missed benefit, workflow negated any potential benefit.Imaging (ESCAPE-MeVO):🔴 Salvageable Tissue Required: Focused EVT on those with potential benefit, but specific criteria could have biased selection. Impact: Potential exclusion of treatable patients.🔴 Device Mandate (ESCAPE-MeVO):Solitaire X Only: Reduced procedural variability but limited operator choice and real-world applicability. Impact: Potential for suboptimal device selection, skewed real-world applicability.🔴 Mortality (ESCAPE-MeVO):Increased Mortality Signal: Serious concern suggesting potential harm in this specific context. Impact: Strong argument against routine EVT in this population.🔴 Workflow Times:🟢 Prolonged Times (Both, esp. ESCAPE-MeVO): Delays could negate EVT benefits due to irreversible damage. Impact: Undermined potential efficacy.🟢Spontaneous Recanalization (ESCAPE-MeVO):Recanalization Before EVT: Unnecessary EVT in some, diluting treatment effect and cumulating risk. Impact: Obscured potential benefit.

Neurovascular Nugget 22_ Unpacking Aneurysmal Subarachnoid Hemorrhage Treatment

Thu, 26 Mar 2026 15:21:34 GMT

🔔 Clinical Outcomes: Unfavorable Clinical Outcomes: Before PSM, unfavorable clinical outcomes (mRS scores 3-6) were 72.0% for SC and 66.2% for EC (P = .026). After PSM, these were 70.6% for SC and 63.3% for EC (P = .025). In-Hospital Mortality: Before PSM, in-hospital mortality was significantly higher for EC (16.1%) compared to SC (10.5%, P = .003). After PSM, the difference was not significant (EC: 12.7%, SC: 10.4%, P = .384). 🎤 Predictors of Unfavorable Outcomes: 🥁 Common Predictors: WFNS grade V, age older than 70 years, and Fisher CT grade 4 were predictors of unfavorable outcomes in both SC and EC groups. 🥁 SC-Specific Predictors: WFNS grade IV and Fisher CT grade 3 were associated with unfavorable outcomes only in the SC group. 🥁 EC-Specific Predictors: Ages in the 50s and 60s were associated with unfavorable outcomes only in the EC group. 🎤 Conclusion: EC was associated with significantly more favorable clinical outcomes than SC in patients with poor-grade aSAH, without significant differences in in-hospital mortality after PSM. The benefit of EC over SC might be particularly notable in patients with WFNS grade IV and Fisher CT grade 3. 📣 📣 Implications on Clinical Practice ✅ Treatment Strategy Shift: The findings suggest that EC may be preferred over SC for patients with poor-grade aSAH due to better clinical outcomes at discharge. This could lead to a shift in treatment protocols favoring EC, especially in high-risk cases. ✅ Patient Selection: Clinicians might consider WFNS grade IV and Fisher CT grade 3 as indicators for opting for EC over SC. Understanding the specific predictors of unfavorable outcomes can help tailor treatment plans to individual patient profiles, potentially improving overall outcomes. ✅ Age Considerations: With older age being a significant predictor of unfavorable outcomes, more careful consideration and possibly more aggressive management might be necessary for elderly patients undergoing either EC or SC. ✅ Resource Allocation: High-volume cerebrovascular centers equipped to perform both SC and EC may need to allocate more resources and training towards enhancing EC capabilities, given its demonstrated advantages. ✅ Guideline Revisions: The study’s results might influence revisions of existing guidelines from bodies such as the American Heart Association/American Stroke Association and European Stroke Organization to reflect the potential superiority of EC in poor-grade aSAH cases.

Neurovascular Nugget 25_ Unpacking L-Stenting for Wide-Neck Aneurysms

Thu, 26 Mar 2026 15:21:35 GMT

### Main Points🛜. Effectiveness: - High rate of adequate occlusion (88.7%). - 59.4% complete occlusion at last follow-up.🛜. Safety: - 17 complications in 12 patients (9.4%). - No intraoperative or periprocedural aneurysmal ruptures.🛜. Technique: - Single-stent L-stenting is effective and reduces the amount of metal used compared to dual-stent techniques.🛜. Comparison: - Favorable outcomes compared to other techniques like Y-stenting and new devices like the WEB device.🛜. Predictors: - Smaller aneurysm size and transcellular technique predict better outcomes. - Larger size and dome to neck ratio predict higher retreatment rates.### Clinical Implications ###✅**Treatment Choice:** - Single-stent L-stenting presents a viable alternative to dual-stent techniques, potentially reducing thromboembolic complications and procedural costs.✅ Patient Selection: - Patients with smaller aneurysms and those suitable for the transcellular technique may benefit most from L-stenting.✅ Procedure Planning: - Understanding predictors of success and retreatment can aid in better patient selection and pre-procedural planning.✅ Benchmarking: - This study provides a validated comparator for future studies on new devices and techniques for WNBAs, setting a benchmark for efficacy and safety.✅ Cost Considerations: - L-stenting could be more cost-effective due to the reduced use of stents and lower complication rates, though further studies are needed to confirm this.https://lnkd.in/dU984vPT

Neurovascular-Nugget 21_ Optimizing Thrombectomy Passes

Thu, 26 Mar 2026 15:21:32 GMT

Clinical Implications: - Early switching to the combined technique after failed standalone stent retriever or aspiration passes may improve reperfusion rates.- Repeating the same standalone technique after failed passes may not improve reperfusion as much as early switching.- More data needed to confirm impact on clinical outcomes.

https://jnis.bmj.com/content/early/2024/04/04/jnis-2024-021545

Neurovascular-Nugget 18_ Unpacking Intermittent Oro-Esophageal Tube Feeding in Stroke Recovery

Thu, 26 Mar 2026 15:21:30 GMT

The main points of the article "Effect of Intermittent Oro-Esophageal Tube Feeding in Bulbar Palsy After Ischemic Stroke: A Randomized Controlled Study" are: 1. The study compared the effects of intermittent oro-esophageal tube feeding (IOE) versus nasogastric tube feeding (NG) in patients with bulbar palsy after ischemic stroke who received routine treatment and swallowing rehabilitation training. 2. 148 patients were randomly divided into IOE (n=74) and NG (n=74) groups. 3. The primary outcome was nutritional status (body mass index, serum albumin, prealbumin). Secondary outcomes included swallowing function (Functional Oral Intake Scale, Penetration-Aspiration Scale), pneumonia, depression, and adverse events. 4. After treatment, the IOE group showed significantly better results compared to the NG group in terms of: - Nutritional status (body mass index, albumin, prealbumin) - Swallowing function (Functional Oral Intake Scale, Penetration-Aspiration Scale) - Lower incidence of stroke-associated pneumonia (4.05% vs 35.14%) - Lower incidence of depression (1.35% vs 59.46%) - Fewer adverse events (reflux, fever, throat discomfort) 5. The authors concluded that in patients with dysphagia and bulbar palsy after ischemic stroke receiving routine treatment and swallowing rehabilitation, IOE is safer and more conducive to improving nutritional status, swallowing function, pneumonia, and depression compared to NG. In summary, this randomized controlled study found intermittent oro-esophageal tube feeding to be superior to nasogastric tube feeding across multiple outcomes in stroke patients with bulbar palsy and dysphagia. https://lnkd.in/djPt7Kim

Neurovascular-Nuggets_ Menopause, Brain Blood Flow, and Cerebrovascular Risk

Thu, 26 Mar 2026 15:21:28 GMT

Main Points: - This cross-sectional MRI study looked at cerebral blood flow (CBF) in premenopausal, perimenopausal, and postmenopausal women compared to similar-aged men. - Premenopausal women had higher CBF in whole brain, gray matter, and white matter compared to the other groups. - Perimenopausal and postmenopausal women had more white matter hyperintensities (WMHs) than premenopausal women and men. - Multivariate regression analysis showed menopause status and the interaction of age and menopause status significantly affected CBF. - Premenopausal women showed slight CBF increases with age, while peri- and postmenopausal women showed CBF declines. Clinical Implications: - The findings suggest alterations in brain perfusion begin during perimenopause, possibly due to increased WMHs. - Monitoring brain perfusion changes in perimenopausal women could help identify those at higher cerebrovascular disease risk. - Strategies to maintain better brain perfusion during the menopausal transition may help reduce future cerebrovascular risk. - CBF could be a useful neuroimaging biomarker for cerebrovascular risk during menopause. - Longitudinal studies are needed to clarify how menopause-related CBF changes correlate to outcomes. Read more at hashtag#neurovascularnuggets https://lnkd.in/dRNp95kY

Neurovascular Nuggets_ Navigating DAPT Duration Post-SACE

Thu, 26 Mar 2026 15:21:27 GMT

Main Points - This was a multicenter randomized controlled trial comparing long-term (12 months) vs short-term (3 months) dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after stent-assisted coil embolization (SACE) for cerebral aneurysms. - 142 patients were recruited and randomized. The primary outcome was ischemic stroke rate during 3-12 months after SACE. - There was no significant difference in ischemic stroke rates between the long-term and short-term DAPT groups (0 vs 2.1 per 100 person-years). - Rates of the secondary outcomes (death/any stroke, hemorrhagic events, death/stroke/hemorrhage, retreatment/stent issues) were also not significantly different between groups. - The trial was underpowered due to lower than expected enrollment and event rates. Implications for Clinical Practice - This trial did not find a statistically significant benefit of long-term over short-term DAPT after SACE, but was underpowered to definitively determine this. - The low ischemic event rates suggest DAPT for 3-6 months is likely sufficient for many patients after SACE with newer generation stents. However, longer DAPT may still benefit some high thromboembolic risk patients. - Platelet function testing to guide personalized DAPT duration decisions may be useful. Patients at high hemorrhagic risk may also benefit from shorter DAPT. - Large definitive randomized trials are still needed to determine optimal DAPT duration after SACE. In the meantime, decisions can be individualized based on thromboembolic vs hemorrhagic risk factors Read more at hashtag#neurovascularnuggets https://lnkd.in/dC9Wxhxt

Neurovascular-Nuggets_ Unpacking SAC vs. Coiling for Aneurysms – Is Less Sometimes More_

Thu, 26 Mar 2026 15:21:25 GMT

🎁key points from the article - This was a randomized trial comparing stent-assisted coiling (SAC) versus coiling alone (CA) for unruptured intracranial aneurysms at high risk of recurrence (large, recurrent, or wide-neck aneurysms). - 205 patients were randomized, with 94 allocated to SAC and 111 to CA. The primary outcome was a composite of treatment failure, defined as initial failure, aneurysm rupture, retreatment, death/disability, or residual aneurysm at 12 months imaging. - The primary outcome occurred in 30.1% with SAC versus 27.3% with CA (relative risk 1.10, p=0.66). There was no significant difference in rates of 12-month morbidity/mortality or retreatment. - As-treated analysis showed lower residual aneurysm rates with SAC but higher complication rates compared to CA. - The study did not find evidence that SAC improves outcomes compared to CA in high-risk unruptured aneurysms. 💡Clinical Implications: - The results do not support routine use of SAC over CA in unruptured intracranial aneurysms, even those at higher recurrence risk. - SAC may increase procedural risks without improving clinical outcomes compared to CA. However, the study was underpowered for definitive safety conclusions. - Careful consideration of risks versus benefits is warranted before routinely using SAC instead of CA in eligible unruptured aneurysm patients. - Larger randomized trials could help clarify if subsets of aneurysms benefit from SAC over CA. Integrating future SAC studies into ongoing trials may be useful. In summary, this randomized trial did not find evidence to support superiority of SAC over CA for unruptured intracranial aneurysms prone to recurrence. The results argue against routine use of SAC in eligible patients, though larger studies are needed to guide optimal patient selection. Read more at https://lnkd.in/dwisZ3VA

Neurovascular-Nuggets_ Re-evaluating Reperfusion Targets in Large Ischemic Strokes

Thu, 26 Mar 2026 15:21:23 GMT

🎁the key points from the article - The study retrospectively compared outcomes of endovascular therapy (EVT) achieving modified Thrombolysis in Cerebral Infarction (mTICI) grade 2b (incomplete reperfusion) versus grade 3 (complete reperfusion) in patients with large ischemic strokes. - In 226 patients with large anterior circulation strokes and baseline Alberta Stroke Program Early CT Score (ASPECTS) of 3-5, there was no significant difference in 90-day functional outcomes based on the modified Rankin Scale (mRS) between those with final mTICI 2b versus mTICI 3 reperfusion. - Rates of 90-day mortality and independent ambulation were also similar between mTICI 2b and mTICI 3 groups. - However, symptomatic intracranial hemorrhage (sICH) rates were lower with mTICI 3 compared to mTICI 2b reperfusion (4.5% vs 12.6%). - In subgroup analyses, mTICI 3 reperfusion did not provide added benefit over mTICI 2b reperfusion regardless of patient age, sex, baseline stroke severity, etc. - This suggests mTICI 2b may be an acceptable angiographic endpoint for EVT in large strokes, questioning the need for additional maneuvers to achieve full mTICI 3 reperfusion. 💡Clinical Implications: - The findings suggest interventionalists should carefully weigh risks/benefits of pursuing mTICI 3 if mTICI 2b reperfusion is achieved early in EVT for large ischemic strokes. - mTICI 2b may provide comparable outcomes to mTICI 3 in these patients, while reducing procedural risks such as sICH. - Intraprocedurally evaluating extent of persisting hypoperfusion versus established infarct on imaging could help determine whether to continue manipulating beyond mTICI 2b. - The results may help guide individualized decision making on optimal angiographic targets during EVT for large strokes. More data is needed to develop definitive recommendations. In summary, this study questions the clinical benefit of mandating mTICI 3 reperfusion in EVT for large anterior circulation strokes. It may support stopping at mTICI 2b in some patients to limit procedural risks based on individual characteristics. Read more at hashtag#neurovascularnuggets https://lnkd.in/diJUE4qy

Neurovascular-Nuggets_ Unpacking AF Detection and Stroke Risk

Thu, 26 Mar 2026 15:21:22 GMT

Neurovascular-Nuggets (12) 🎁the key points from the article: - The study compared risk of recurrent stroke and outcomes between ECG-detected and prolonged cardiac monitoring (PCM)-detected atrial fibrillation (AF) in patients with ischemic stroke/TIA. - ECG-detected AF was associated with a 5-fold higher risk of recurrent ischemic stroke compared to PCM-detected AF, even after adjusting for anticoagulation use and other factors. - PCM-detected AF had lower cardiovascular risk profiles, better cardiac parameters, and lower stroke recurrence rates compared to ECG-detected AF. - PCM-detected AF burden was low, with median 5 hours duration and 2.23% burden over 14 days. Higher burden AF (>24 hrs) occurred in 29% of PCM-detected cases. - ECG-detected AF likely represents pre-existing, high burden AF compared to PCM-detected AF in stroke patients. 💡Clinical implications: - There is significant heterogeneity in thromboembolic risk between ECG-detected and PCM-detected AF after stroke/TIA. - ECG-detected AF should not be considered similar to PCM-detected AF and may warrant different clinical risk stratification. - PCM-detected AF still carries an important stroke recurrence risk that warrants anticoagulation, especially in higher burden AF. - Distinguishing between AF diagnostic types is important for prognosis and management of stroke patients with newly diagnosed AF. In summary, differentiating between ECG- and PCM-detected AF has implications for risk stratification and treatment decisions in stroke patients with newly diagnosed AF. Read more at hashtag#neurovascularnuggets https://lnkd.in/dFPFQfBA

Neurovascular Nuggets_ Unraveling Pediatric Circulatory Disorders

Thu, 26 Mar 2026 15:21:09 GMT

This is very important review that provides a comprehensive summary of mechanical cervicocerebral circulatory disorders in children, with several key implications: - It emphasizes that pediatric patterns differ substantially from adults for these conditions. For bow hunter's syndrome, pediatric cases primarily involve the upper cervical spine (C1-C2) with vertebral artery dissection, while adults more commonly have lower cervical disease related to spondylosis. - Recognition that bow hunter's syndrome is a major cause of posterior circulation stroke in children is critically important. Appropriate diagnosis with catheter angiography and head rotations is needed to guide surgical management and prevent recurrence. - The high rate of recurrent stroke with medical management alone found by Rollins et al (80% recurrence) highlights the need for definitive surgical treatment in pediatric bow hunter's syndrome. This differs from the lower recurrence rates with medical therapy in adults. - For Eagle's syndrome, the review highlights that symptomatic internal carotid artery compression or dissection is very rare in children compared to adults. However, diagnosis with provocative vascular imaging and surgical treatment principles are similar. - Growing evidence indicates symptomatic jugular venous compression can occur in children, causing headaches or cognitive issues. The entity is likely underdiagnosed currently. - Dynamic venography showing reversible flow changes or elevated gradients with head positioning is key to definitively diagnosing jugular compression syndromes. This differs from traditional thinking that venous drainage should not be posture-dependent. - The provided examples demonstrate how bony anatomical variants in children likely increase their risk for developing these disorders compared to adults. Recognition of high-risk anatomy on CT or MRI is important. - The review emphasizes that catheter angiography remains the gold standard for diagnosis of these disorders, as it provides the best combination of dynamic information and anatomical detail with head provocation maneuvers. Overall, the paper greatly improves understanding of how pediatric mechanical circulatory disturbances differ from adults. This will support prompt recognition and appropriate diagnosis and management in children presenting with concerning symptoms or posterior circulation events. Read more at hashtag#neurovascularnuggets https://lnkd.in/dKkCypyS

Neurovascular Nuggets_ The ENRICH Trial - A Turning Point for ICH Surgery

Thu, 26 Mar 2026 15:21:07 GMT

turning point in the nihilism surrounding surgery for ICH Based on my review, here are the key points about the results and findings: This article discusses the results of the ENRICH trial, which evaluated minimally invasive surgery plus thrombolysis (MIPS) compared to medical management for the treatment of spontaneous lobar intracerebral hemorrhage (ICH). The key findings are: The ENRICH trial met its primary endpoint, demonstrating that MIPS led to superior functional outcomes at 6 months compared to medical management alone in patients with lobar ICH. MIPS was associated with higher rates of hematoma evacuation and lower mortality compared to medical management. An adaptive trial design allowed early stopping of enrollment for patients with anterior basal ganglia ICH due to futility, limiting the conclusions to lobar ICH. Uncommon but methodologically sound features of the trial design included use of a utility-weighted mRS, Bayesian statistics, and an adaptive design. These results are a major breakthrough, providing the first robust evidence that surgical evacuation can improve outcomes in a select group of ICH patients. Prior large randomized trials showed no benefit of surgery over medical management. The success of ENRICH appears due to improved patient selection, surgical technique, and timing compared to prior studies. It parallels recent successes for endovascular thrombectomy in ischemic stroke. The findings will likely lead to an increased role for minimally invasive surgery in guidelines and clinical practice for lobar ICH meeting ENRICH criteria. Key outstanding questions remain regarding optimal patient selection, timing, and surgical techniques. Direct comparative effectiveness studies with other interventions like endoscopic evacuation are still needed. Implementation may be limited by resource availability, especially in lower income regions. Overall though, this trial represents an exciting turning point in the nihilism surrounding surgery for ICH. Read more at hashtag#neurovascularnuggets https://lnkd.in/d94Fdxgp

Neurovascular Nuggets_ Unpacking Intracranial Hypertension in CVT

Thu, 26 Mar 2026 15:21:05 GMT

Based on reviewing the paper , here are the key points about the results and findings: - The study found that 46% of patients with acute cerebral venous sinus thrombosis (CVT) had evidence of intracranial hypertension (IH), based on elevated CSF pressure, papilledema, or optic disc protrusion. - IH was associated with higher thrombus volume, thrombosis of the dominant transverse sinus, superior sagittal sinus (SSS) thrombosis alone or combined with transverse sinus, and more thrombosed segments when bilateral transverse sinus thrombosis was absent. - Thrombus volume had the strongest association with elevated CSF pressure on linear regression. Volumes over 4ml were associated with higher risk of IH. - Dominant transverse sinus thrombosis was the most influential predictor of IH based on multivariate analysis. - The authors conclude that large thrombus volume and thrombosis of strategic venous segments like the SSS and dominant transverse sinus are risk factors for IH in CVT patients. - These findings align with some previous studies showing associations between dominant transverse sinus thrombosis and IH. However, the importance of thrombus volume and extensive SSS thrombosis are novel findings. - The implications are that patients with high-risk features like large thrombus volume and strategic sinus occlusions may benefit from closer monitoring and evaluation for IH after a CVT diagnosis. This could prevent complications like vision loss. In summary, this study identified potential imaging markers to predict IH risk in CVT patients, which could guide clinical monitoring and management. The findings on thrombus volume are new and require further confirmation. Read more at hashtag#neurovascularnuggets https://lnkd.in/dQEHv4hg

Neurovascular-Nuggets (8)_ Flow Diversion for Compressive ICA Aneurysms – A Deep Dive

Thu, 26 Mar 2026 15:21:03 GMT

Flow diversion for compressive unruptured internal carotid artery aneurysms with neuro- ophthalmological symptoms: a systematic review and meta-analysis Results - 22 studies included, 594 patients treated with flow diverters for compressive ICA aneurysms - Pooled rates of symptom recovery: 47.4% complete, 74.5% improvement - Rates of transient worsening: 7.1%, permanent worsening: 4.9% - Isolated visual symptoms: 30.6% complete recovery, 56.6% improvement - Isolated oculomotor symptoms: 47.8% complete recovery, 78% improvement - Aneurysm complete occlusion rate: 68.6% - Morbidity rate: 5%, mortality rate: 3.9% Comparison to Previous Research - Recovery rates are comparable to previous meta-analyses on surgical clipping, coiling, and parent vessel occlusion for similar aneurysms - Morbidity and mortality rates are slightly higher than some previous studies like PUFS trial - Occlusion rates align with other flow diverter studies - Emphasizes importance of early treatment, improving chances of recovery 10-fold if treated within 1 month of symptom onset Applications - Provides evidence for flow diversion as a valid treatment option for compressive ICA aneurysms - Informs clinical decision-making and patient selection for flow diversion - Suggests early treatment is critical for best outcomes - Adds to knowledge of expected recovery rates, risks, and occlusion rates with this technique The results generally confirm flow diversion as an appropriate treatment for these aneurysms, though early intervention is key. The data help set expectations on likelihood of recovery and risks. This study adds a comprehensive analysis to the existing literature on flow diversion for this indication. Read more at hashtag#neurovascularnuggets https://lnkd.in/dYafDCcv

Neurovascular Nuggets_ Tenecteplase vs. Alteplase and the Thrombus Length Mystery

Thu, 26 Mar 2026 15:21:01 GMT

The study included 1865 patients treated with either tenecteplase (n=787) or alteplase (n=1078) before mechanical thrombectomy. - Overall, early recanalization (modified TICI 2b-3) occurred in 19.8% with tenecteplase and 18.5% with alteplase (OR 1.09, 95% CI 0.83-1.44, p=0.52). - There was no significant difference in early recanalization rates between tenecteplase and alteplase based on time from IVT to angiography (Figure 2) or occlusion site (ICA, proximal M1, distal M1, M2) (Figure 3). - However, there was an interaction between treatment and thrombus length (Figure 4). Tenecteplase was associated with higher early recanalization compared to alteplase for thrombi ≥10mm in length (OR 2.43, 95% CI 1.02-5.81, p=0.04). - The authors conclude that overall recanalization rates were similar between tenecteplase and alteplase, but tenecteplase may be more effective than alteplase for early recanalization of larger thrombi before thrombectomy. Compared to previous studies, the results are mixed: The overall early recanalization rates are similar to those reported for both tenecteplase (around 20%) and alteplase (around 20% with longer IVT-to-angiography times) in prior studies. However, some previous studies like EXTEND-IA TNK found higher recanalization with tenecteplase (22%) compared to alteplase (10%). The current study did not replicate this difference. The finding that tenecteplase leads to higher recanalization for larger thrombi is consistent with recent in vitro data, but inconsistent with one prior study using the clot burden score that suggested tenecteplase was more effective for smaller clots. So the results add to conflicting data on whether tenecteplase provides superior early recanalization compared to alteplase before thrombectomy. The interaction with thrombus length is a novel finding and suggests tenecteplase could have particular benefits for larger clots if confirmed. Overall, the study supports current guidelines which recommend tenecteplase over alteplase based on the totality of evidence, but does not definitively demonstrate superior recanalization, especially for smaller distal occlusions. Further randomized controlled trials may be needed to clarify if tenecteplase should be first-line over alteplase. Read more at hashtag#neurovascularnuggets

Neurovascular Nuggets_ Rivaroxaban for Cerebral Venous Thrombosis – Unpacking a Feasibility Trial

Thu, 26 Mar 2026 15:21:00 GMT

Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis Here are the key points from the research article on rivaroxaban vs standard-of-care for cerebral venous thrombosis (CVT): - The study was a randomized controlled feasibility trial conducted at 12 Canadian centers comparing rivaroxaban to standard anticoagulation (warfarin or low molecular weight heparin) for CVT. - 55 participants were enrolled over 2.5 years. The recruitment rate was 21.3 participants per year, meeting feasibility targets. 57% of eligible patients consented to enroll. - Median age was 48 years and 66% were female. Median time from diagnosis to enrollment was 3 days. - One patient on rivaroxaban had a symptomatic intracranial hemorrhage by day 180 (primary safety outcome), compared to none in the control group. Rates of clinically relevant non-major bleeding and recurrent CVT were also numerically higher with rivaroxaban. - All patients had at least partial recanalization by day 180 on imaging. - Despite over 75% having functional independence at baseline per mRS scores, participants reported impairments in quality of life, mood, fatigue, headaches and cognition at enrollment. All patient-reported metrics improved by days 180 and 365. - The authors conclude that recruitment targets were met but consent rates were suboptimal. Early safety signals potentially favor standard anticoagulation but overall event rates were low. Patient-reported outcomes suggest CVT impacts well-being despite mild stroke severity. Larger trials are needed to confirm safety and optimize antithrombotic therapy. Read more at https://lnkd.in/d6aEiydK

Neurovascular-Nuggets (5)_ The Surprising Link Between Long Sleep and Stroke Risk

Thu, 26 Mar 2026 15:20:58 GMT

In an investigation into the cardiovascular health disparities among racially and ethnically diverse populations, the Northern Manhattan Study (NOMAS) examined the correlation between sleep duration and subclinical carotid atherosclerosis, a precursor to stroke. The study controlled for a range of sociodemographic and lifestyle variables. The results, based on 1,553 community-dwelling adults, revealed a pronounced association between long sleep duration (≥9 hours) and increased presence and area of carotid plaque, independent of other risk factors. Conversely, short sleep duration (<7 hours) and daytime sleepiness showed no significant correlation with carotid atherosclerosis markers. These findings suggest that extended sleep duration may serve as an independent risk factor for carotid atherosclerosis, thereby providing a potential mechanistic link between long sleep and elevated stroke risk. The paper also explores potential mechanisms linking sleep duration to carotid atherosclerosis. Long sleep has been correlated with metabolic imbalances, inflammatory markers, and certain behavioral risk factors, all of which are implicated in cardiovascular disease. Despite these observations, causality remains unclear. The study suggests that targeted interventions aimed at sleep duration could serve as a novel pathway to mitigate carotid atherosclerotic burden, although further research is needed to elucidate the underlying mechanisms. Read more at hashtag#neurovascularnuggets https://lnkd.in/dxmdspRG

Decoding Carotid Stent Design_ A Deep Dive into Embolization Risk

Thu, 26 Mar 2026 15:20:56 GMT

This study aimed to evaluate the influence of carotid stent design on the risk of embolization during carotid artery stenting. Specifically, the research contrasted the volume of embolized material caught by filters during the procedure, using stents of different designs, namely, open-cell stents (OCS), closed-cell stents (CCS), and micromesh stents (MMS). The study was retrospective and conducted on patients with asymptomatic carotid stenosis above 70%, who underwent carotid artery stenting in an Italian medical institution between 2010 and 2022. The main focus, or primary end point, was the ratio of particulate material-to-total filter area, known as the embolic filter debris (EFD) load. The secondary endpoints studied were 30-day major stroke and death rates. Results from 481 carotid artery stentings revealed that 35% used OCS, 14% used CCS, and 50% used MMS. The 30-day mortality and major stroke rate was low at 0.2%. Interestingly, the use of MMS resulted in the cleanest filters (41% free from embolized material), and had a lower EFD load compared to other stent designs. These findings remained consistent even after adjusting for plaque characteristics. In conclusion, micromesh stents seemed to be associated with a lessened embolization risk during carotid artery stenting, as evidenced by lower embolic filter debris load and more filters free from particulate matter. Nevertheless, further studies will be necessary to confirm these findings and potentially guide the choice of stent design in clinical practice. https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043117?fbclid=IwAR25o0dKZYcQ3jUu1QfQYF5vN4z4-1eZNy0PoDZ4kNZqDSTK5NNAs4WNcko_aem_AUsuUyz0w5Mxg2DeftDGbvclFpXMGjtUtewhrI7kK3F05PRr4TWYwArurR4uzLNbHaE